Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
Dexcom (NASDAQ: DXCM) announces that the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now eligible for provincial coverage in Manitoba for individuals with type 1 diabetes aged 25 and under. This move expands access to CGM technology, joining other provinces like British Columbia and Quebec that already provide coverage. The Dexcom G6 system allows users to monitor glucose levels continuously, reducing reliance on fingerstick tests. The initiative aims to improve diabetes management and health outcomes for young individuals with diabetes in Manitoba.
Dexcom (NASDAQ: DXCM) announces its G6 Continuous Glucose Monitoring (CGM) System is now covered by the Non-Insured Health Benefits (NIHB) Program for children and adolescents aged 2-19 requiring intensive insulin therapy. This coverage aims to improve access for First Nations and Inuit communities, potentially enhancing health outcomes for those living with diabetes. With proven benefits in glycemic control, the Dexcom G6 System provides real-time data and alerts, facilitating better diabetes management and support for families.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Jereme Sylvain, CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 2:00 PM EST. Quentin Blackford, COO, will present at the Morgan Stanley 19th Annual Healthcare Conference on September 13, 2021, at 2:00 PM EST. Webcasts will be available on the DexCom Investor Relations site for live viewing and future reference.
DexCom reported second quarter 2021 financial results with revenue growth of 32% year-over-year, totaling $595.1 million. U.S. revenue increased by 26%, while international revenue saw a remarkable 58% growth. GAAP operating income reached $101.0 million (17% of revenue), up 200 basis points from the previous year. DexCom announced an increase in its 2021 revenue guidance to approximately $2.35 - 2.40 billion, reflecting strong momentum in the CGM market. The company also received FDA clearance for its real-time API.
DexCom has received FDA clearance for its real-time Partner Web APIs, enabling third-party developers to integrate continuous glucose monitoring (CGM) data into digital health apps and devices. This advancement aims to enhance user experience by providing more flexibility in viewing glucose data. Companies like Garmin and Teladoc Health's Livongo are involved in the integration process. The APIs will help users consolidate therapy data and receive personalized diabetes management coaching.
DexCom, Inc. (NASDAQ:DXCM) will release its Q2 2021 financial results on July 29, 2021, after the market closes. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the performance. Investors can access the call by dialing (800) 446-1671 for US/Canada or (847) 413-3362 for international calls, using the confirmation number 49591483. The call will also be webcast live, and the link will be available on the DexCom investor relations website.
DexCom, Inc. (NASDAQ: DXCM) recently highlighted key research at the 81st American Diabetes Association (ADA) virtual conference (June 25-29, 2021). The data emphasizes the critical role of continuous glucose monitoring (CGM) in diabetes management across various populations. Notably, presentations included analyses on CGM's effects on hypoglycemia control, glycemic control improvements, and healthcare cost reductions among Type 2 diabetes patients. Additionally, the conference showcased over a dozen studies linking CGM to enhanced health outcomes and quality of life.
DexCom (NASDAQ:DXCM) has launched The Global Movement for Time in Range, a campaign aimed at enhancing awareness and adoption of time in range metrics in diabetes management. Co-led by Nick Jonas, the initiative is backed by various diabetes organizations, aiming to inform patients about time in range's benefits and improve healthcare strategies. Survey data indicates that many insulin-treated diabetes patients lack awareness of this crucial metric, highlighting a significant opportunity for education and improved healthcare practices. The movement seeks to address these knowledge gaps.
Dexcom and Tandem Diabetes Care support Canadian athlete Sébastien Sasseville in his 14-day cycling challenge across Canada to raise awareness for diabetes technology access. The endeavor aims to highlight disparities in access to continuous glucose monitoring (CGM) systems across provinces. Recent announcements regarding public coverage of CGM systems in Quebec, Saskatchewan, and British Columbia reflect progress, yet inequalities persist. Sasseville uses the t:slim X2 insulin pump and Dexcom G6 CGM to manage his type 1 diabetes during the ride.
Dexcom (NASDAQ: DXCM) announces expanded provincial coverage for the Dexcom G6 CGM System through BC PharmaCare for individuals aged two years and older on intensive insulin therapy. This initiative aims to enhance diabetes management, providing broader access to life-changing technology. Notable endorsements from medical professionals highlight the positive impact of CGM on glycemic control and reduction in emergency room visits due to severe hypoglycemia. BC now joins other provinces in Canada offering public coverage for CGM systems.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
